Vacina para AIDS???

Será?

doi:10.1016/j.vaccine.2008.12.017    

Copyright © 2008 Elsevier Ltd All rights reserved.

Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge

John Schell^a, Nina F. Rose^a, Nicole Fazo^a, Preston A. Marx^b, Meredith Hunter^b, Elizabeth Ramsburg^c, David Montefiori^c, Patricia Earl^d, Bernard Moss^d and John K. Rose^a

 Abstract

In an earlier study, our group vaccinated rhesus macaques with vesicular stomatitis virus (VSV) vectors expressing Gag, Pol, and Env proteins from a hybrid simian/human immunodeficiency virus (SHIV). This was followed by a single boost with modified vaccinia virus Ankara (MVA) vectors expressing the same proteins. Following challenge with SHIV89.6P, vaccinated animals cleared challenge virus RNA from the blood by day 150 and maintained normal CD4 T cell counts for 8 months. Here we report on the long-term (>5-year post-challenge) status of these animals and the immunological correlates of long-term protection. Using real-time PCR, we found that viral DNA in peripheral blood mononuclear cells (PBMCs) of the vaccinees declined continuously and fell to below detection (<5 copies/10⁵ cells) by approximately 3 years post-challenge. SHIV DNA was also below the limit of detection in the lymph nodes of two of the four animals at 5 years post-challenge. We detected long-term persistence of multi-functional Gag-specific CD8⁺ T cells in both PBMCs and lymph nodes of the two protected animals with the Mamu A*01⁺ MHC I allele. All animals also maintained SHIV89.6P neutralizing antibody titers for 5 years. Our results show that this vaccine approach generates solid, long-term control of SHIV infection, and suggest that it is mediated by both cytotoxic T lymphocytes and neutralizing antibody.

Keywords: SHIV89.6P; Vaccine; VSV; MVA; Rhesus; Long-term